follow us:Google+ FacebookLinkedInTwitterRSS Feeds

advertisement

Savient partnering with Swedish firm to market arthritis treatment

By

Back to Top Comments Email Print

Latest News

advertisement

Savient Pharmaceuticals Inc., in Bridgewater, announced today it is partnering with Sobi, of Stockholm, to promote Kineret, a treatment for rheumatoid arthritis, in the United States.

Savient is a specialty biopharmaceutical company that has developed and commercialized the gout treatment Krystexxa, which it continues to market.

According to the announcement, Sobi has granted Savient the exclusive rights to co-promote the sale of Kineret with Sobi in the United States. Sobi will remain responsible for all Kineret commercial drug manufacturing, supply, safety and regulatory activities.

 

 

 

Share This Story On:

Write to the Editorial Department at editorial@njbiz.com

advertisement

Comments


Be the first to comment.



Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
     View Comment Policy

Advanced search
Sponsored by
advertisement
  
  
advertisement
  
  
advertisement
Back to Top